OBJECTIVE: To ascertain the rate of initial drug resistance and transmission patterns of Mycobacterium tuberculosis in Kampala, Uganda. SETTING: National Tuberculosis (TB) Treatment Centre, Mulago Hospital, Kampala, Uganda and Case Western Reserve University, Cleveland, Ohio, USA and McClellan Memorial Veterans Hospital, Little Rock, Arkansas, USA. METHODS: Using a radiometric BACTEC 460 TB system, susceptibility of 215 M. tuberculosis isolates from previously untreated patients from Kampala, Uganda (age range, 17-48 years, mean, 28 years; 56% males and 69% human immunodeficiency virus (HIV)-seropositive) was determined for isoniazid, rifampin, streptomycin and ethambutol. Isolates from 73 patients, selected on the basis of geographical location, were tested for strain diversity or relatedness using the IS6110 DNA fingerprinting technique. RESULTS: Resistance rates were as follows: isoniazid, 7.9% streptomycin, 6.1% rifampin, 1.4% and ethambutol 0.9%. Twelve per cent of the strains were resistant to at least one of the first line drugs tested and 4.7% were multiply resistant. There were no significant differences in resistance rates between patients with and without HIV infection. Using the number and size of DNA fragments containing IS6110, only three clusters of isolates with identical RFLP patterns were found out of the 73 isolates tested (8.2%). Each cluster contained two isolates. Three (4.1%) isolates had less than seven copies of IS6110. CONCLUSION: This study shows that in Uganda initial drug resistance rates to anti-tuberculosis agents are low and similar to other sub-Saharan African countries and that multiple strains of M. tuberculosis have been transmitted within the community.
OBJECTIVE: To ascertain the rate of initial drug resistance and transmission patterns of Mycobacterium tuberculosis in Kampala, Uganda. SETTING: National Tuberculosis (TB) Treatment Centre, Mulago Hospital, Kampala, Uganda and Case Western Reserve University, Cleveland, Ohio, USA and McClellan Memorial Veterans Hospital, Little Rock, Arkansas, USA. METHODS: Using a radiometric BACTEC 460 TB system, susceptibility of 215 M. tuberculosis isolates from previously untreated patients from Kampala, Uganda (age range, 17-48 years, mean, 28 years; 56% males and 69% human immunodeficiency virus (HIV)-seropositive) was determined for isoniazid, rifampin, streptomycin and ethambutol. Isolates from 73 patients, selected on the basis of geographical location, were tested for strain diversity or relatedness using the IS6110 DNA fingerprinting technique. RESULTS: Resistance rates were as follows: isoniazid, 7.9% streptomycin, 6.1% rifampin, 1.4% and ethambutol 0.9%. Twelve per cent of the strains were resistant to at least one of the first line drugs tested and 4.7% were multiply resistant. There were no significant differences in resistance rates between patients with and without HIV infection. Using the number and size of DNA fragments containing IS6110, only three clusters of isolates with identical RFLP patterns were found out of the 73 isolates tested (8.2%). Each cluster contained two isolates. Three (4.1%) isolates had less than seven copies of IS6110. CONCLUSION: This study shows that in Uganda initial drug resistance rates to anti-tuberculosis agents are low and similar to other sub-Saharan African countries and that multiple strains of M. tuberculosis have been transmitted within the community.
Entities:
Keywords:
Africa; Africa South Of The Sahara; Antibiotics; Bacterial And Fungal Diseases; Biology; Clinical Research; Developing Countries; Diseases; Drugs; Eastern Africa; English Speaking Africa; Genetics; Infections; Research Methodology; Research Report; Treatment; Tuberculosis; Uganda
Authors: Benson R Kidenya; Lauren E Webster; Sehan Behan; Rodrick Kabangila; Robert N Peck; Stephen E Mshana; Oksana Ocheretina; Daniel W Fitzgerald Journal: Tuberculosis (Edinb) Date: 2013-09-07 Impact factor: 3.131
Authors: Beth Temple; Irene Ayakaka; Sam Ogwang; Helen Nabanjja; Susan Kayes; Susan Nakubulwa; William Worodria; Jonathan Levin; Moses Joloba; Alphonse Okwera; Kathleen D Eisenach; Ruth McNerney; Alison M Elliott; Peter G Smith; Roy D Mugerwa; Jerrold J Ellner; Edward C Jones-López Journal: Clin Infect Dis Date: 2008-11-01 Impact factor: 9.079
Authors: Christopher C Whalen; Sarah Zalwango; Allan Chiunda; LaShaunda Malone; Kathleen Eisenach; Moses Joloba; W Henry Boom; Roy Mugerwa Journal: PLoS One Date: 2011-02-14 Impact factor: 3.240
Authors: Sam Ogwang; Benon B Asiimwe; Hamidou Traore; Francis Mumbowa; Alphonse Okwera; Kathleen D Eisenach; Susan Kayes; Edward C Jones-López; Ruth McNerney; William Worodria; Irene Ayakaka; Roy D Mugerwa; Peter G Smith; Jerrold Ellner; Moses L Joloba Journal: BMC Infect Dis Date: 2009-08-26 Impact factor: 3.090
Authors: Benon B Asiimwe; Moses L Joloba; Solomon Ghebremichael; Tuija Koivula; David P Kateete; Fred A Katabazi; Alexander Pennhag; Ramona Petersson; Gunilla Kallenius Journal: BMC Infect Dis Date: 2009-02-05 Impact factor: 3.090
Authors: Deus Lukoye; Francis Adatu; Kenneth Musisi; George William Kasule; Willy Were; Rosemary Odeke; Julius Namonyo Kalamya; Ann Awor; Anand Date; Moses L Joloba Journal: PLoS One Date: 2013-08-01 Impact factor: 3.240
Authors: Mariam O Fofana; Sourya Shrestha; Gwenan M Knight; Ted Cohen; Richard G White; Frank Cobelens; David W Dowdy Journal: Antimicrob Agents Chemother Date: 2017-02-23 Impact factor: 5.191